The limitations of persistence as a measure of efficacy of biologic therapies
British Journal of Dermatology · 16.11.2023 · 189 (6) · e100-e101
DOI: 10.1093/bjd/ljad322 ↗Kurz gefasst
Editorial in der Zeitschrift British Journal of Dermatology, online erschienen am 06.09.2023. Verfasst von Robert S Stern. Beteiligte Einrichtung: Department of Dermatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA. Hauptthemen laut MEDLINE: Psoriasis, Biological Products. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 6 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
ORCID-Profile: Robert S Stern
Zitieren
APA
Stern, R. S. (2023). The limitations of persistence as a measure of efficacy of biologic therapies. British Journal of Dermatology, 189(6), e100-e101. https://doi.org/10.1093/bjd/ljad322
Vancouver
Stern RS. The limitations of persistence as a measure of efficacy of biologic therapies. British Journal of Dermatology. 2023;189(6):e100-e101. doi:10.1093/bjd/ljad322
BibTeX
@article{Stern2023,
author = {Stern, Robert S},
title = {The limitations of persistence as a measure of efficacy of biologic therapies},
journal = {British Journal of Dermatology},
year = {2023},
volume = {189},
number = {6},
pages = {e100--e101},
doi = {10.1093/bjd/ljad322}
}
EUVIMED